Journal of Clinical Oncology, Vol 21, Issue 9
(May), 2003: 1688-1697
© 2003 American Society for Clinical Oncology
High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
Regine Schneider-Stock,
Carsten Boltze,
Jerzy Lasota,
Markku Miettinen,
Brigitte Peters,
Matthias Pross,
Albert Roessner,
Thomas Günther
From the Department of Pathology, Department of Biometrics, Department of General Surgery, Otto-von-Guericke University, Magdeburg, Germany; and Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC.
Address reprint requests to Regine Schneider-Stock, PhD, Department of Pathology, Otto-von-Guericke University, Leipziger Str 44, 39120 Magdeburg, Germany; email: regine.schneider-stock{at}medizin.uni-magdeburg.de.
Purpose: Gastrointestinal stromal tumors (GISTs) represent a distinctive (but histologically heterogeneous) group of neoplasms, the malignant potential of which is often uncertain. To determine the prognostic relevance of p16INK4 alterations in GISTs, we investigated a larger group of GISTs and correlated the genetic findings with clinicopathological factors and patient survival.
Material and Methods: We evaluated the methylation status of the promotor by methylation-specific polymerase chain reaction (PCR), the presence of mutations by PCR-SSCP-sequencing, the loss of heterozygosity at the p16INK4 locus (using the c5.1 marker), and the immunohistochemical expression of p16INK4 protein in 43 GISTs in 39 patients.
Results: p16INK4 alterations were found in 25 of 43 GISTs (58.1%), with benign, borderline, or malignant GISTs showing no differences in the type and frequency of alteration. p16INK4 alterations were correlated with a loss of p16INK4 protein expression (P < .01). Patients who had tumors with p16INK4 alterations had a poorer prognosis than patients with tumors without such alterations (P = .02). There was a high predictive value for p16INK4 alterations only in the group of benign and borderline GISTs (P < .01) with regard to clinical outcome. Univariate Coxs proportional hazard regression analysis revealed a strong correlation between p16INK4 alterations, tumor size, mitotic index, and overall survival (P < .02), whereas multivariate Coxs analysis confirmed only p16INK4 alterations as an independent prognostic factor.
Conclusion: We believe that the evaluation of p16INK4 alteration status is a helpful prognosticator, particularly in the benign and borderline groups of GISTs.
Supported in part by Mildred-Scheel Foundation grant no. 10-1501.
We thank Hiltraud Scharfenort and Antje Schinlauer for their expert technical assistance.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H.-Y. Huang, S.-H. Li, S.-C. Yu, F.-F. Chou, C.-C. Tzeng, T.-H. Hu, Y.-H. Uen, Y.-F. Tian, Y.-H. Wang, F.-M. Fang, et al.
Homozygous Deletion of MTAP Gene as a Poor Prognosticator in Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
November 15, 2009;
15(22):
6963 - 6972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kikuta, M. Gotoh, T. Kanda, N. Tochigi, T. Shimoda, T. Hasegawa, H. Katai, Y. Shimada, Y. Suehara, A. Kawai, et al.
Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities
Jpn. J. Clin. Oncol.,
October 7, 2009;
(2009)
hyp125v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Romeo, M. Debiec-Rychter, M. Van Glabbeke, H. Van Paassen, P. Comite, R. Van Eijk, J. Oosting, J. Verweij, P. Terrier, U. Schneider, et al.
Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
June 15, 2009;
15(12):
4191 - 4198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sulong, A. V. Moorman, J. A. E. Irving, J. C. Strefford, Z. J. Konn, M. C. Case, L. Minto, K. E. Barber, H. Parker, S. L. Wright, et al.
A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups
Blood,
January 1, 2009;
113(1):
100 - 107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Suehara, T. Kondo, K. Seki, T. Shibata, K. Fujii, M. Gotoh, T. Hasegawa, Y. Shimada, M. Sasako, T. Shimoda, et al.
Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics
Clin. Cancer Res.,
March 15, 2008;
14(6):
1707 - 1717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Meza-Zepeda, S. H. Kresse, A. H. Barragan-Polania, B. Bjerkehagen, H. O. Ohnstad, H. M. Namlos, J. Wang, B. E. Kristiansen, and O. Myklebost
Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas.
Cancer Res.,
September 15, 2006;
66(18):
8984 - 8993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L Tornillo and L M Terracciano
An update on molecular genetics of gastrointestinal stromal tumours.
J. Clin. Pathol.,
June 1, 2006;
59(6):
557 - 563.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Haller, B. Gunawan, A. von Heydebreck, S. Schwager, H.-J. Schulten, J. Wolf-Salgo, C. Langer, G. Ramadori, H. Sultmann, and L. Fuzesi
Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
September 15, 2005;
11(18):
6589 - 6597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Martin, A. Poveda, A. Llombart-Bosch, R. Ramos, J. A. Lopez-Guerrero, J. G. del Muro, J. Maurel, S. Calabuig, A. Gutierrez, J. L. G. de Sande, et al.
Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)
J. Clin. Oncol.,
September 1, 2005;
23(25):
6190 - 6198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schneider-Stock, C. Boltze, J. Lasota, B. Peters, C. L. Corless, P. Ruemmele, L. Terracciano, M. Pross, L. Insabato, D. Di Vizio, et al.
Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study
Clin. Cancer Res.,
January 15, 2005;
11(2):
638 - 645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Corless, J. A. Fletcher, and M. C. Heinrich
Biology of Gastrointestinal Stromal Tumors
J. Clin. Oncol.,
September 15, 2004;
22(18):
3813 - 3825.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|